JPWO2020227546A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020227546A5 JPWO2020227546A5 JP2021566008A JP2021566008A JPWO2020227546A5 JP WO2020227546 A5 JPWO2020227546 A5 JP WO2020227546A5 JP 2021566008 A JP2021566008 A JP 2021566008A JP 2021566008 A JP2021566008 A JP 2021566008A JP WO2020227546 A5 JPWO2020227546 A5 JP WO2020227546A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor antigen
- population
- specific
- apcs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024011014A JP2024038503A (ja) | 2019-05-08 | 2024-01-29 | Ｔ細胞製造組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845251P | 2019-05-08 | 2019-05-08 | |
| US62/845,251 | 2019-05-08 | ||
| PCT/US2020/031898 WO2020227546A1 (en) | 2019-05-08 | 2020-05-07 | T cell manufacturing compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024011014A Division JP2024038503A (ja) | 2019-05-08 | 2024-01-29 | Ｔ細胞製造組成物および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022531474A JP2022531474A (ja) | 2022-07-06 |
| JPWO2020227546A5 true JPWO2020227546A5 (https=) | 2023-05-16 |
| JP2022531474A5 JP2022531474A5 (https=) | 2023-05-16 |
| JP7582971B2 JP7582971B2 (ja) | 2024-11-13 |
Family
ID=73051205
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566008A Active JP7582971B2 (ja) | 2019-05-08 | 2020-05-07 | Ｔ細胞製造組成物および方法 |
| JP2024011014A Pending JP2024038503A (ja) | 2019-05-08 | 2024-01-29 | Ｔ細胞製造組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024011014A Pending JP2024038503A (ja) | 2019-05-08 | 2024-01-29 | Ｔ細胞製造組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220280621A1 (https=) |
| EP (1) | EP3965784A4 (https=) |
| JP (2) | JP7582971B2 (https=) |
| KR (2) | KR102756321B1 (https=) |
| CN (2) | CN121086984A (https=) |
| AR (1) | AR118859A1 (https=) |
| AU (1) | AU2020268397A1 (https=) |
| BR (1) | BR112021022363A2 (https=) |
| CA (1) | CA3137037A1 (https=) |
| IL (1) | IL287874A (https=) |
| MX (1) | MX2021013608A (https=) |
| PH (1) | PH12021552829A1 (https=) |
| SG (1) | SG11202112346WA (https=) |
| TW (2) | TWI777160B (https=) |
| WO (1) | WO2020227546A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3101122B1 (en) | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| PT2812431T (pt) | 2012-02-09 | 2019-10-18 | Baylor College Medicine | Pepmixes para gerar ctls multivirais com larga especifidade |
| JP6999941B2 (ja) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | 病原体からの免疫原性抗原同定および臨床的有効性との相関 |
| CA3081840A1 (en) | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
| KR20210040355A (ko) * | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
| TWI777160B (zh) * | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| EP4114400A4 (en) * | 2020-03-05 | 2023-10-18 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| US20230374455A1 (en) * | 2020-08-13 | 2023-11-23 | Biontech Us Inc. | T cell manufacturing compositions and methods |
| US11948694B2 (en) * | 2021-05-12 | 2024-04-02 | Merative Us L.P. | Controlling compartmental flows in epidemiological modeling based on mobility data |
| US12062456B2 (en) | 2021-05-27 | 2024-08-13 | Merative Us L.P. | Hypothetical scenario evaluation in infectious disease dynamics based on similar regions |
| IL312121A (en) * | 2021-10-15 | 2024-06-01 | Biontech Us Inc | T cell manufacturing compositions and methods |
| WO2023159088A1 (en) * | 2022-02-15 | 2023-08-24 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
| IL321246A (en) * | 2022-12-09 | 2025-08-01 | Biontech Us Inc | Compositions and methods for producing T cells |
| WO2024151124A1 (ko) * | 2023-01-12 | 2024-07-18 | 주식회사 이뮤노맥스 | 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법 |
| CN117417886B (zh) * | 2023-10-20 | 2024-05-14 | 广东壹加再生医学研究院有限公司 | 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276478B2 (en) * | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| WO2006110582A1 (en) * | 2005-04-08 | 2006-10-19 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
| DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US9809797B2 (en) * | 2007-10-03 | 2017-11-07 | National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology | Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression |
| EP2749639B1 (en) * | 2012-02-10 | 2016-10-12 | Hakushinkouseikai Foundation | Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
| RU2763795C2 (ru) * | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| DE102015214780A1 (de) * | 2015-08-03 | 2017-02-09 | Continental Automotive Gmbh | Verfahren zur Erkennung fehlerhafter Komponenten eines Kraftstoffeinspritzsystems |
| AU2016306408B2 (en) * | 2015-08-10 | 2021-02-11 | Toray Industries, Inc. | Immune inducer |
| EP3347051A4 (en) * | 2015-09-10 | 2019-04-24 | Affigen, Inc. | SEQUENCING SELECTING TUMOR THEROSTICAS |
| WO2017059557A1 (en) * | 2015-10-09 | 2017-04-13 | Peking University | Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use |
| AU2018337960B2 (en) * | 2017-09-20 | 2025-08-14 | Neximmune, Inc. | Cell compositions comprising antigen-specific T cells for adoptive therapy |
| CA3081840A1 (en) * | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
| TWI777160B (zh) * | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
-
2020
- 2020-05-05 TW TW109114957A patent/TWI777160B/zh active
- 2020-05-05 TW TW111130596A patent/TWI867324B/zh active
- 2020-05-05 AR ARP200101269A patent/AR118859A1/es unknown
- 2020-05-07 KR KR1020217040167A patent/KR102756321B1/ko active Active
- 2020-05-07 CA CA3137037A patent/CA3137037A1/en active Pending
- 2020-05-07 US US17/609,705 patent/US20220280621A1/en active Pending
- 2020-05-07 AU AU2020268397A patent/AU2020268397A1/en active Pending
- 2020-05-07 CN CN202511339181.5A patent/CN121086984A/zh active Pending
- 2020-05-07 JP JP2021566008A patent/JP7582971B2/ja active Active
- 2020-05-07 PH PH1/2021/552829A patent/PH12021552829A1/en unknown
- 2020-05-07 SG SG11202112346WA patent/SG11202112346WA/en unknown
- 2020-05-07 KR KR1020247036158A patent/KR20240161214A/ko active Pending
- 2020-05-07 CN CN202080050310.8A patent/CN114096261B/zh active Active
- 2020-05-07 BR BR112021022363A patent/BR112021022363A2/pt unknown
- 2020-05-07 WO PCT/US2020/031898 patent/WO2020227546A1/en not_active Ceased
- 2020-05-07 EP EP20801696.4A patent/EP3965784A4/en active Pending
- 2020-05-07 MX MX2021013608A patent/MX2021013608A/es unknown
-
2021
- 2021-11-07 IL IL287874A patent/IL287874A/en unknown
-
2024
- 2024-01-29 JP JP2024011014A patent/JP2024038503A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020227546A5 (https=) | ||
| Moskowitz et al. | Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients—results of a phase I/II trial | |
| Kradin et al. | Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer | |
| Weinblatt et al. | Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: a one‐year randomized, placebo‐controlled study | |
| Lillehei et al. | Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy | |
| JP6162778B2 (ja) | ワクチン免疫療法 | |
| Hauschild et al. | Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG) | |
| Berookhim et al. | Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept | |
| Otvos et al. | Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome | |
| AU2020383021A1 (en) | Renal cell carcinoma (RCC) therapy using genetically engineered T cells targeting CD70 | |
| Vonderheid et al. | Extracorporeal photopheresis in psoriasis vulgaris: clinical and immunologic observations | |
| Osanto et al. | Immunization with Interleukin-2 Transfected Melanoma Cells. A Phase I–II Study in Patients with Metastatic Melanoma. University Hospital Leiden | |
| US20180318347A1 (en) | Methods for treating cancer | |
| CN106890330A (zh) | Dc‑cik细胞和抗pd‑1抗体组合物及其用途 | |
| CN116790744B (zh) | 一种缺血性心脏病晚期纤维化干预靶点及其应用 | |
| Wen et al. | A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma | |
| Margolin et al. | Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer | |
| CA3125773A1 (en) | Therapeutic rna for advanced stage solid tumor cancers | |
| CN121622884A (zh) | 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途 | |
| Rini et al. | Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity | |
| JP2025003730A (ja) | 癌患者への免疫チェックポイント阻害薬の投与の有効性を予測するためのデータを収集する方法 | |
| Dillman et al. | Dendritic cell vaccines presenting autologous tumor antigens from self-renewing cancer cells in metastatic renal cell carcinoma | |
| KR20260033049A (ko) | 전립선암 치료 방법 | |
| KR20200019229A (ko) | B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료 | |
| JP5807769B2 (ja) | 頭頚部癌の治療に用いる、腫瘍栄養動脈に投与される抗癌細胞組成物の使用 |